Ten years of experience of biologics in juvenile idiopathic arthritis: focus for the reasons of withdrawals

Table 1

	All biologics	Infliximab	Abatacept	Tocilizumab	Adalimumab	Etanercept
Withdrawal reasons
Adverse events	40	25	3	5	2	4
Inefficacy	51	21	16	1	4	5
Other	32	14	1	2	13	2
Therapy duration before withdrawal
Half a year	4	2	0	2	0	0
One year	36	16	7	2	7	3
Two years	17	7	4	1	0	3
Three years and more	17	11	2	0	2	1

ISSN: 1546-0096